• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Aebersold Award Presented to Goldenberg

Posted on: Tuesday, 20 September 2005, 03:00 CDT

David M. Goldenberg, ScD, MD, founder and president of the Garden State Cancer Center and the Center for Molecular Medicine and Immunology (Belleville, NJ), received the 2005 Paul C. Aebersold Award for outstanding achievement in basic science applied to nuclear medicine on June 19 at the 52nd Annual Meeting of the SNM, held in Toronto, Canada.

The Aebersold Award is named for Paul C. Aebersold, a pioneer in the biologic and medical application of radioactive materials and the first director of the Atomic Energy Commission's Division of Isotope Development at Oak Ridge, Tenn. The first Aebersold Award was given by SNM in 1973. "I am humbled to be among these giants of nuclear medicine," said Goldenberg. "I am especially grateful to the society for recognizing me, a nonnuclear physician, for my contributions to basic science applied to nuclear medicine. Science often takes us down unpredictable paths, and I certainly did not plan to conduct nuclear medicine research when I embarked on cancer biology, pathology, immunology, and genetics."

Stanley Goldsmith, MD, (left) introduced David Goldenberg, who was presented the Aebersold Award by SNM President Mathew L. Thakur, PhD.

Goldenberg pioneered the development of radiolabeled antibodies for various applications in the detection, diagnosis, and therapy of cancer. Under his leadership, scientists and clinicians at the Garden State Cancer Center have developed antibodies for the diagnosis, detection, and treatment of solid tumors such as colorectal, pancreatic, lung, breast, and ovarian cancers, as well as hematologie cancers such as lymphoma and multiple myeloma. He has overseen the in-house clinic as well as clinical outreach at affiliated institutions in the United States and Europe for treatment of cancer patients with radiolabeled antibodies. He also helped develop 2 diagnostic radiopharmaceuticals marketed by Immunomedics Inc., which he established in 1982. He is also the president and chief executive officer of CMMI, a notfor-profit, independent, specialized research center that focuses on the development of biological strategies to detect and treat cancer and immunological diseases.

Over the past 30 years, Goldenberg has been a major contributor to knowledge of the basic principles of the preparation and utilization of radioimmunoconjugates in medical diagnosis, including functional imaging and guided radionuclide therapy. He has published more than 500 articles in peer-reviewed journals and is currently exploring the use of PET tracers in immunodiagnosis and therapy, especially by pretargeting methods he and his colleagues are developing, and the use of new humanized antibodies for the treatment of lymphomas and autoimmune diseases. He has edited 2 books on radiolabeled antibodies and 10 journal supplements to Cancer, Cancer Research, and Clinical Cancer Research.

He has received numerous professional awards and recognition by scientific bodies, including McGiIl University, the Indian Society of Nuclear Medicine (Sarabhai Memorial Oration), the Swedish Oncology and Radiology Societies (Elis Bervin Lecture/Medal), the International Society for Oncodevelopmental Biology and Medicine (Abbott Award), the German Cancer Fund, the National Institutes of Health (NIH; twice Outstanding Investigator Grant awardee), Tel Aviv University, the British Radiology Society (3M Mayneord Memorial Award), and the Clinical Ligand Assay Society (Distinguished Scientist Award).

Goldenberg received an SB degree from the University of Chicago in 1958, an ScD from the Faculty of Natural Sciences of the University of Erlangen-Nuremberg in 1965, and his MD from the University of Heidelberg's School of Medicine in 1966. He has faculty appointments in pathology at the University of Pittsburgh, Temple University, and the University of Kentucky and adjunct professorships in medicine, surgery, and microbiology/immunology at the University of Medicine and Dentistry of New Jersey and New York Medical College. He is currently an editorial board member of several journals, including The Journal of Nuclear Medicine, the International Journal of Tumor Markers, the Quarterly Journal of Nuclear Medicine and Molecular Imaging, Current Medical Imaging Reviews, Current Cancer Therapy Reviews, and Cancer Biotherapy and Radiopharmaceuticals. He has also served as chair of the merit review board in oncology for the Veterans Administration and a member of the Experimental Immunology Study section of NIH.

Copyright Society of Nuclear Medicine Sep 2005

Source: Journal of Nuclear Medicine, The

More News in this Category